lucky quotes

lucky quotes KANSAS CITY, Mo. — Taylor Swift once raved about the sweet potato casserole served at a New York City restaurant and now that recipe pops up every now and again at Thanksgiving. The holidays encourage many of us to try new recipes. Social media right now is flooded with recipes for appetizers, side dishes and desserts. Anyone making that cornbread casserole from TikTok? While we might not get to share a Thanksgiving feast with Swift — is your name Blake Lively? — or other celebrities beloved by Kansas City, we can eat like them. So here’s the recipe for that casserole Swift loved so much, and favorite family side dish recipes from Donna Kelce and Eric Stonestreet. Enjoy. Travis Kelce's mother, Donna Kelce, seen here last year at her son's music festival, dined on a cheesesteak made by actor Bradley Cooper at QVC festivities in Las Vegas this week. (Emily Curiel/Kansas City Star/TNS) Emily Curiel//Kansas City Star/TNS If we tried to guess how many holiday dinner rolls Travis Kelce and his brother, Jason Kelce, have scarfed over the years, would it be in the hundreds? Thousands? Their mom has spoken often about the batches of holiday crescent rolls she has baked over the years. Based on the recipe that won the 1969 Pillsbury Bake-Off, Pillsbury’s Magic Marshmallow Crescent Puffs , they’re now known as Mama Kelce’s Dinner Rolls. They blend the crescent roll pastry with marshmallows, cinnamon and sugar. Dinner roll or dessert? We bet they didn’t last long enough in front of Travis and Jason for that debate. Ingredients Rolls •1/4 cup granulated sugar •2 tablespoons Pillsbury Best all-purpose flour •1 teaspoon ground cinnamon •2 (8-ounce) cans refrigerated Pillsbury Original Crescent Rolls (8 Count) •16 large marshmallows •1/4 cup butter or margarine, melted Glaze •1/2 cup powdered sugar •1/2 teaspoon vanilla •2-3 teaspoons milk •1/4 cup chopped nuts Directions Make the rolls 1. Preheat oven to 375°F. Spray 16 medium muffin cups with nonstick baking spray. 2. In a small bowl, mix the granulated sugar, flour and cinnamon. 3. Separate the dough into 16 triangles. For each roll, dip 1 marshmallow into melted butter; roll in the sugar mixture. Place marshmallow on the shortest side of a triangle. Roll up, starting at shortest side and rolling to opposite point. Completely cover the marshmallow with the dough; firmly pinch edges to seal. Dip 1 end in remaining butter; place butter side down in muffin cup. 4. Bake for 12 to 15 minutes or until golden brown. 5. When done, remove from the oven and let the puffs cool in the pan for 1 minute. Remove rolls from muffin cups; place on cooling racks set over waxed paper. Make the glaze and assemble In a small bowl, mix the powdered sugar, vanilla and enough milk for desired drizzling consistency. Drizzle glaze over warm rolls. Sprinkle with nuts. Serve warm. Eric Stonestreet attends 'Eric Stonestreet visits The SiriusXM Hollywood Studios in Los Angeles' at SiriusXM Studios on Oct. 8, 2019, in Los Angeles. (Emma McIntyre/Getty Images for SiriusXM/TNS) Emma McIntyre/Getty Images North America/TNS Thanksgiving is one of the “Modern Family” star’s favorite holidays. Three years ago, as part of a campaign honoring hometown heroes , he shared one of his favorite recipe with McCormick Spices: Roasted Brussels Sprouts with Bacon and Butternut Squash . This recipe serves eight. Ingredients •1 pound Brussels sprouts, trimmed and halved •1 pound butternut squash, peeled and cut into bite-size cubes •1 tablespoon olive oil •1/2 teaspoon garlic powder •1/2 teaspoon thyme leaves •1/2 teaspoon salt •1/4 teaspoon ground black pepper •5 slices bacon, chopped •1 shallot, finely chopped •1/2 cup dried cranberries •1/4 cup balsamic vinegar •1 teaspoon whole grain mustard •1/2 cup chopped pecans, toasted (optional) •1/3 cup crumbled blue cheese, (optional) Directions 1. Preheat oven to 475°F. Spray large shallow baking pan with no stick cooking spray; set aside. Place Brussels sprouts and squash in large bowl. Drizzle with olive oil and sprinkle with garlic powder, thyme, salt and pepper; toss to coat evenly. Spread in single layer on prepared pan. 2. Roast 16 to 18 minutes or until tender and lightly browned, stirring halfway through cooking. 3. Meanwhile, cook bacon in medium skillet on medium heat about 6 minutes or until crispy. Remove using slotted spoon and place on paper towels to drain. Add shallot to same skillet; cook and stir 2 minutes until softened and lightly browned. Stir in cranberries, vinegar and mustard until well blended. Transfer mixture to small bowl; set aside. 4. Arrange roasted Brussels sprouts and squash on serving platter. Drizzle with cranberry balsamic glaze and toss gently to coat. Sprinkle with cooked bacon, toasted pecans, and crumbled blue cheese, if desired. Serve immediately. Donna Kelce, left, mother of Chiefs tight end Travis Kelce watched the game with pop superstar Taylor Swift, center, during the first-half on Sunday, Sept. 24, 2023, at GEHA Field at Arrowhead Stadium in Kansas City. (Tammy Ljungblad/Kansas City Star/TNS) Tammy Ljungblad/Kansas City Star/TNS Swift gushed about the sweet potato casserole served at Del Frisco’s Grille in New York City, a dish crowned with a crunchy candied pecan and oatmeal crumble. “I’ve never enjoyed anything with the word casserole in it ever before, but it’s basically sweet potatoes with this brown sugary crust,” she told InStyle. ”Oh my God, it’s amazing.” The media rushed to find the recipe, which Parade has published this Thanksgiving season . “Similar to T. Swift herself, we think this recipe is a mastermind, especially if you’ve been asked to bring the sweet potato side dish to this year’s Thanksgiving feast. It seriously begs the question: who needs pumpkin pie?” the magazine writes. Ingredients •4 lbs sweet potatoes •1⁄3 cup oats •12 oz unsalted butter, divided •1⁄2 cup packed brown sugar •1⁄2 cup toasted pecans •1⁄2 cup granulated sugar •1 tsp kosher salt •2 tsp vanilla extract •4 large eggs, beaten Directions Preheat oven to 375°F. 1. Scrub sweet potatoes. Pierce each several times with a fork and wrap tightly in foil. Place on a sheet pan. Bake 90 minutes or until tender. Set aside until cool enough to handle. 2. Meanwhile, place oats in a food processor; process 1 minute. Add 4 oz butter, brown sugar and pecans; pulse five times to combine. Spread mixture on a baking sheet; bake 10 minutes. Remove from oven, crumble. Bake 5 minutes or until golden brown. 3. Melt remaining 8 oz butter. Remove skin from cooled sweet potatoes. In a large bowl, whisk sweet potatoes, melted butter, granulated sugar and remaining ingredients until slightly lumpy. Transfer to a greased baking dish, smoothing surface evenly. Top with oat mixture. Bake 12 minutes or until heated through. Make-ahead tips •Sweet potato filling can be made up to 2 days in advance. Prepare the sweet potato filling, cool, place in a casserole dish and keep refrigerated. •Oat-pecan crust can also be made up to 2 days ahead. Make the crust according to recipe directions, cool and store in an airtight container at room temperature. Sprinkle over the sweet potato filling just before baking.

PM leads Romania presidential vote first roundCybercrimes in Telangana spiked by 43 percent this year: Annual report

tomch/iStock Unreleased via Getty Images Alphabet Inc. ( NASDAQ: GOOGL ) ( NASDAQ: GOOG ) remains one of our favorite tech coverage picks for the mid-to long-term guys. We're updating our thoughts on the stock after Bloomberg reported that the Tired of losing money? Our Tech Contrarians team of Wall Street analysts sifts through the noise in the tech industry and captures outperformers through a coveted research process. We let the work speak for itself here . Tech Stock Pros is a team of three former technology sector engineers with a long history of investing in the tech sector. Tech Contrarians Learn more Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Châtillon, France, December 11 th , 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old DBV and FDA aligned on key study design elements for the COMFORT Toddlers study in 1 – 3 year-olds, including study size and wear time collection methodology and analysis COMFORT Toddlers study on-track to initiate in 2Q 2025 Viaskin Peanut patch BLA submission for the Toddlers indication anticipated for 2H 2026 FDA confirmed criteria for post-marketing confirmatory study in toddlers 1 – 3 years-old Company to host investor webcast today at 5:00pm ET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the successful outcome of recent written and oral communication with the U.S. Food and Drug Administration (FDA) that provides a clear and well-defined regulatory pathway for the Viaskin Peanut patch program in toddlers 1 – 3-years-old. The FDA has formalized guidance on an Accelerated Approval for the Viaskin Peanut patch in toddlers 1 – 3-years-old. DBV and FDA have agreed on the key design elements for a post-marketing confirmatory study. “DBV is pleased to have received, what we believe to be, a clear and reasonable pathway towards an Accelerated Approval for the Viaskin Peanut patch in toddlers 1 – 3-years-old. This comes on the heels of our October 22 nd press release announcing details in support of our separate Viaskin Peanut programs in 4 – 7 year-olds and in 1 – 7 year-olds in Europe,” said Daniel Tassé, Chief Executive Officer, DBV Technologies. “We believe we have decreased the regulatory pathway risk of our programs. DBV can now fully focus on executing the remaining studies that will support two distinct BLAs across age groups and an MAA in Europe. We are grateful to the Agency for its attentive collaboration as we continue to work towards introducing this novel therapy to caregivers and patients as expeditiously as possible.” Accelerated Approval Pathway The FDA recently issued written communication confirming an Accelerated Approval pathway for the Viaskin Peanut patch in toddlers 1 – 3-years-old. As a reminder, current FDA guidance for Accelerated Approval includes three qualifying criteria: That the product candidate treats a serious condition That the product candidate generally provides a meaningful advantage over available therapies That the product candidate demonstrates an effect or an intermediate clinical endpoint that is reasonably likely to predict clinical benefit As DBV previously announced , FDA confirmed via written communication that the Viaskin Peanut patch already met criteria one and two. FDA and DBV have been engaged in ongoing dialogue throughout Q4 of this year regarding the intermediate clinical endpoint necessary to meet the third criterion. In the recent written communication, the FDA confirmed the efficacy data from the Company’s Phase 3 EPITOPE study can serve as an intermediate clinical endpoint. The FDA has agreed that the endpoint is reasonably likely to predict clinical benefit and will therefore fulfill the requirement for Accelerated Approval. In preparation for commercialization, DBV made slight modifications to the Viaskin Peanut patch used in EPITOPE to increase the simplicity of application for the caregiver and provide product identification on each patch. No changes, including patch shape or size, were made to the device components that are in contact with the patient’s skin. Further, to increase the volume of patch production for future commercialization, changes needed to be made to the manufacturing process and location. Although the intended commercial Viaskin Peanut patch is currently being used (N=304) in the ongoing 3-year Open Label Extension to EPITOPE, the collective changes to the commercial Viaskin Peanut patch were viewed by the FDA as constituting a different product relative to the clinical patch used in the EPITOPE study. The Company intends to use the commercial Viaskin Peanut patch in both the COMFORT Toddlers study and the post-marketing confirmatory study. Post-Marketing Confirmatory Study In the recent written communication, FDA confirmed criteria for a post-marketing confirmatory study in toddlers 1 – 3-years-old. DBV and FDA agreed that the confirmatory study will assess the effectiveness of the intended commercial Viaskin Peanut patch and will need to be initiated at the time that the BLA is submitted. To date, the commercial patch has been used in 304 subjects with over 234,695 patient-days of therapy in the placebo crossover and the EPITOPE Open Label Extension, with no clinically relevant differences in efficacy or safety vs. the clinical patch used in the EPITOPE Phase 3 trial. The confirmatory study will include a double-blind, placebo-controlled food challenge (DBPCFC) and will use the same statistical criteria for success (i.e., lower bound of the 95% CI > 15%) as used in the EPITOPE Phase 3 efficacy study. Adhesion data for the post-marketing confirmatory study will be collected in a similar manner relative to the COMFORT Toddlers study. The Company expects these data will further support the importance of average daily wear time in the use of the Viaskin Peanut patch as it relates to efficacy and labeling. “When it comes to food allergy management, what works for one family, might not work for another. That is why having varied treatment options available is so incredibly important to our community,” said Sung Poblete, PhD, RN, CEO of FARE (Food Allergy Research & Education). “I’m pleased to learn that DBV’s constructive dialogue with the FDA has resulted in this Accelerated Approval guidance outlining remaining developmental steps for the Viaskin Peanut patch in toddlers with a peanut allergy. At FARE, we look forward to the possibility that one day, if approved, caregivers and families will have this exciting new treatment as an option to consider.” COMFORT Toddlers Supplemental Safety Study COMFORT Toddlers is a Phase 3 double-blind, placebo-controlled (DBPC) study designed to generate additional safety (primary endpoint) and adhesion data of the Viaskin Peanut patch in peanut allergic toddlers 1 – 3-years old. DBV is pleased to announce that Dr. Julie Wang, MD, Professor of Pediatrics, Jaffe Food Allergy Institute, the Icahn school of Medicine at Mount Sinai, will act as the Global Principal Investigator for the COMFORT Toddlers study. “I am thrilled to assume the role of Global Principal Investigator of the COMFORT Toddlers study,” stated Dr. Julie Wang, Professor of Pediatrics, Jaffe Food Allergy Institute, Icahn school of Medicine at Mount Sinai in New York. “Viaskin Peanut, if approved, would offer a much-needed alternative treatment option for patients and caregivers. I look forward to working with the DBV team to advance this important clinical trial.” The Company anticipates that COMFORT Toddlers will enroll approximately 480 subjects randomized 3:1 (active: placebo) at approximately 80 – 90 study centers across the U.S., Canada, Australia, and Europe. COMFORT Toddlers will be a six-month study followed by an optional 18-month open-label treatment phase, to provide 24 or 18 months of treatment with the Viaskin Peanut patch for participants randomized to the active or placebo groups, respectively. Thus, the COMFORT Toddlers study will increase the total subjects exposed to the Viaskin Peanut patch for at least six-months in a controlled study to 600, as required by FDA. In total, there will be approximately 240 subjects with the clinical patch in EPITOPE and 360 with the commercial patch in COMFORT Toddlers. As previously disclosed , DBV and FDA have aligned on a patch wear time collection methodology, analysis and study objective hierarchy in the COMFORT Toddlers study. The agreed-upon adhesion data collection methodology provides a practical approach for subjects, families, and investigators. The methodology is intended to generate sufficient data to support a BLA submission under the Accelerated Approval pathway (i.e., collecting patch adhesion data with a focus on daily wear time at relevant time points). We believe there are three positive outcomes coming out of the productive discussions with FDA: FDA agreed that adhesion would not be a co-objective of a safety study and would be an exploratory endpoint. Next, adhesion should be assessed in the overall totality of benefit to risk (i.e., in the context of efficacy and safety). The third success is that we have aligned on what DBV believes is a very feasible approach to collecting adhesion data. DBV has initiated study start-up activities and plans to screen the first subject in the second quarter of 2025. Biologic License Application Submission in 1 – 3 Year-Olds There will be two Phase 3 studies in 1 – 3-year-olds using the Viaskin Peanut patch. The data generated from the studies will be used to inform a BLA submission: Twelve months of DBPC efficacy and safety data from the previously completed Phase 3 EPITOPE study (published in the New England Journal of Medicine i n May 2023), and 36 months of open-label extension data. Six months of DBPC data generated in COMFORT Toddlers supplemental safety study. DBV anticipates that the BLA for the Viaskin Peanut patch in toddlers 1 – 3 years-old under the Accelerated Approval program will be submitted in 2H 2026. Investor Conference Call and Webcast DBV management will host an investor conference call and webcast today, Wednesday, December 11 th , at 5:00pm EST, to discuss these regulatory updates. This call is accessible via the below teleconferencing numbers and requesting the DBV Technologies call. United States: +1-877-346-6112 International: +1-848-280-6350 A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/ . A replay of the presentation will also be available on DBV’s website after the event. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary Viaskin® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPITTM), the Viaskin® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309). For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn . Forward Looking Statements This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of Viaskin® Peanut patch and EPITTM, designs of DBV’s anticipated clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, plans and expectations regarding initiation of the confirmatory study, plans and expectations with respect to COMFORT Toddlers and COMFORT Children, plans and expectations with respect to the submission of BLAs to FDA, anticipated support for the BLA submission, DBV’s expectations with respect to the Accelerated Approval pathway and any other actionable regulatory pathway, and the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”), DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 7, 2024, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release. Viaskin is a registered trademark and EPIT is a trademark of DBV Technologies. Investor Contact Katie Matthews DBV Technologies katie.matthews@dbv-technologies.com Media Contact Angela Marcucci DBV Technologies angela.marcucci@dbv-technologies.com Attachment PDF Version

Prospera Financial Services Inc lessened its position in SPDR Portfolio S&P 500 Growth ETF ( NYSEARCA:SPYG – Free Report ) by 98.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,780 shares of the company’s stock after selling 340,963 shares during the quarter. Prospera Financial Services Inc’s holdings in SPDR Portfolio S&P 500 Growth ETF were worth $562,000 at the end of the most recent reporting period. Other institutional investors and hedge funds have also recently modified their holdings of the company. Sei Investments Co. increased its holdings in SPDR Portfolio S&P 500 Growth ETF by 20.1% during the 1st quarter. Sei Investments Co. now owns 6,013 shares of the company’s stock worth $440,000 after purchasing an additional 1,006 shares during the period. O Shaughnessy Asset Management LLC boosted its position in shares of SPDR Portfolio S&P 500 Growth ETF by 34.0% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 10,387 shares of the company’s stock valued at $760,000 after purchasing an additional 2,634 shares during the period. Waverly Advisors LLC boosted its position in shares of SPDR Portfolio S&P 500 Growth ETF by 100.5% in the 1st quarter. Waverly Advisors LLC now owns 337,707 shares of the company’s stock valued at $24,703,000 after purchasing an additional 169,288 shares during the period. Dynasty Wealth Management LLC acquired a new stake in shares of SPDR Portfolio S&P 500 Growth ETF in the 1st quarter valued at about $262,606,000. Finally, B. Riley Wealth Advisors Inc. boosted its position in shares of SPDR Portfolio S&P 500 Growth ETF by 138.1% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 134,658 shares of the company’s stock valued at $9,850,000 after purchasing an additional 78,111 shares during the period. SPDR Portfolio S&P 500 Growth ETF Stock Performance SPDR Portfolio S&P 500 Growth ETF stock opened at $86.30 on Friday. SPDR Portfolio S&P 500 Growth ETF has a twelve month low of $62.33 and a twelve month high of $87.94. The stock has a 50 day moving average of $84.04 and a two-hundred day moving average of $80.41. The stock has a market capitalization of $29.62 billion, a price-to-earnings ratio of 27.22 and a beta of 1.14. SPDR Portfolio S&P 500 Growth ETF Company Profile SPDR S&P 500 Growth ETF (the Fund), formerly SPDR Dow Jones Large Cap Growth ETF, focuses to provide investment results, which correspond to the total return performance of an index tracks the performance of exchange traded the equity securities. The SPDR S&P 500 Growth ETF matches the returns and characteristics of the S&P 500 Growth Index (the Index). See Also Want to see what other hedge funds are holding SPYG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR Portfolio S&P 500 Growth ETF ( NYSEARCA:SPYG – Free Report ). Receive News & Ratings for SPDR Portfolio S&P 500 Growth ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR Portfolio S&P 500 Growth ETF and related companies with MarketBeat.com's FREE daily email newsletter .AP Sports SummaryBrief at 6:15 p.m. EST